ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015
Genetic Modulation of Neurocognitive Function in Glioma Patients.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Influences on cognitive outcomes in adult patients with gliomas: A systematic review.Frontiers in oncology · 2022Pooled it
- Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment.Journal of neuro-oncology · 2017Pooled it
- Obstacles and Trials in Treating Primary Brain Tumors.International journal of molecular sciences · 2026Review
- A novel cuproptosis-related genes nomogram on the prognosis and immune microenvironment of breast invasive carcinoma.Scientific reports · 2025Article
- Perioperative Neurocognitive Function in Glioma Surgery.Current oncology reports · 2024Review
- Article
- Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma.Neuro-oncology · 2022Article
- Complications, compliance, and undertreatment do not explain the relationship between cognition and survival in diffuse glioma patients.Neuro-oncology practice · 2022Article
- Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients.Journal of neuro-oncology · 2022Article
- Central Nervous System Plasticity Influences Language and Cognitive Recovery in Adult Glioma.Neurosurgery · 2021Review
- Cognitive impairments are independently associated with shorter survival in diffuse glioma patients.Journal of neurology · 2021Article
- Clinical and Genetic Risk Prediction of Cognitive Impairment After Blood or Marrow Transplantation for Hematologic Malignancy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- NOS1 expression promotes proliferation and invasion and enhances chemoresistance in ovarian cancer.Oncology letters · 2020Article
- Risk Factors for Cognitive Impairment in High-Grade Glioma Patients Treated with Postoperative Radiochemotherapy.Cancer research and treatment · 2020Article
- Genetic Factors of Nitric Oxide's System in Psychoneurologic Disorders.International journal of molecular sciences · 2020Review
- Emerging mechanistic underpinnings and therapeutic targets for chemotherapy-related cognitive impairment.Current opinion in oncology · 2019Review
- Genetic variants and cognitive functions in patients with brain tumors.Neuro-oncology · 2019Article
- Host Genome Variation is Associated with Neurocognitive Outcome in Survivors of Pediatric Medulloblastoma.Translational oncology · 2019Article
- Monitoring of Neurocognitive Function in the Care of Patients with Brain Tumors.Current treatment options in neurology · 2019Review
- Association of genetic variants with fatigue in patients with malignant glioma.Neuro-oncology practice · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeAccumulating evidence supports the contention that genetic variation is associated with neurocognitive function in healthy individuals and increased risk for neurocognitive decline in a variety of patient populations, including cancer patients. However, this has rarely been studied in glioma patients. EXPERIMENTAL
designTo identify the effect of genetic variants on neurocognitive function, we examined the relationship between the genotype frequencies of 10,967 single-nucleotide polymorphisms in 580 genes related to five pathways (inflammation, DNA repair, metabolism, cognitive, and telomerase) and neurocognitive function in 233 newly diagnosed glioma patients before surgical resection. Four neuropsychologic tests that measured memory (Hopkins Verbal Learning Test-Revised), processing speed (Trail Making Test A), and executive function (Trail Making Test B, Controlled Oral Word Association) were examined.
resultsEighteen polymorphisms were associated with processing speed and 12 polymorphisms with executive function. For processing speed, the strongest signals were in IRS1 rs6725330 in the inflammation pathway (P = 2.5 × 10(-10)), ERCC4 rs1573638 in the DNA repair pathway (P = 3.4 × 10(-7)), and ABCC1 rs8187858 in metabolism pathway (P = 6.6 × 10(-7)). For executive function, the strongest associations were in NOS1 rs11611788 (P = 1.8 × 10(-8)) and IL16 rs1912124 (P = 6.0 × 10(-7)) in the inflammation pathway, and POLE rs5744761 (P = 6.0 × 10(-7)) in the DNA repair pathway. Joint effect analysis found significant gene polymorphism-dosage effects for processing speed (Ptrend = 9.4 × 10(-16)) and executive function (Ptrend = 6.6 × 10(-15)).
conclusionsPolymorphisms in inflammation, DNA repair, and metabolism pathways are associated with neurocognitive function in glioma patients and may affect clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.